Patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to either FOLFIRI ( irinotecan @ mg/m ( @ ) day @ , LV @ mg/m ( @ ) as @ h infusion and @-FU @ mg/m ( @ ) as bolus , days @ and @ followed by @ mg/m ( @ ) / day as @ h continuous infusion , q@ for four cycles ) followed by docetaxel @ mg/m ( @ ) day @ , cisplatin @ mg/m ( @ ) day @ , q@ for three cycles ( sequential arm ) or De Gramont regimen ( @-FU/LV arm ) .